Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report.

Oncology letters

Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, DE Vita F.
PMID: 25663920
Oncol Lett. 2015 Mar;9(3):1403-1405. doi: 10.3892/ol.2014.2822. Epub 2014 Dec 23.

Bone metastasis is an uncommon event in advanced gastric cancer patients and bone metastases are rarely detected as isolated lesions. However, eleven years after treatment for locally advanced gastric cancer, including total gastrectomy followed by adjuvant chemotherapy, a 49-year-old...

Cite
Iovino F, Orditura M, Auriemma PP, et al. Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. Oncol Lett. 2014;9(3):1403-1405doi: 10.3892/ol.2014.2822.
Iovino, F., Orditura, M., Auriemma, P. P., Ciorra, F. R., Giordano, G., Orabona, C., Bara, F., Sergio, R., Savastano, B., Fabozzi, A., Laterza, M. M., Ventriglia, J., Petrillo, A., Della Corte, C. M., & DE Vita, F. (2015). Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. Oncology letters, 9(3), 1403-1405. https://doi.org/10.3892/ol.2014.2822
Iovino, Francesco, et al. "Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report." Oncology letters vol. 9,3 (2015): 1403-1405. doi: https://doi.org/10.3892/ol.2014.2822
Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, DE Vita F. Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. Oncol Lett. 2015 Mar;9(3):1403-1405. doi: 10.3892/ol.2014.2822. Epub 2014 Dec 23. PMID: 25663920; PMCID: PMC4315078.
Copy Download .nbib Format: NLM
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.

Molecular and clinical oncology

Riccardi F, Colantuoni G, Diana A, Mocerino C, Cartenì G, Lauria R, Febbraro A, Nuzzo F, Addeo R, Marano O, Incoronato P, De Placido S, Ciardiello F, Orditura M.
PMID: 30155246
Mol Clin Oncol. 2018 Sep;9(3):255-263. doi: 10.3892/mco.2018.1672. Epub 2018 Jul 16.

Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromatase...

Cite
Riccardi F, Colantuoni G, Diana A, et al. Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety. Mol Clin Oncol. 2018;9(3):255-263doi: 10.3892/mco.2018.1672.
Riccardi, F., Colantuoni, G., Diana, A., Mocerino, C., Cartenì, G., Lauria, R., Febbraro, A., Nuzzo, F., Addeo, R., Marano, O., Incoronato, P., De Placido, S., Ciardiello, F., & Orditura, M. (2018). Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety. Molecular and clinical oncology, 9(3), 255-263. https://doi.org/10.3892/mco.2018.1672
Riccardi, Ferdinando, et al. "Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety." Molecular and clinical oncology vol. 9,3 (2018): 255-263. doi: https://doi.org/10.3892/mco.2018.1672
Riccardi F, Colantuoni G, Diana A, Mocerino C, Cartenì G, Lauria R, Febbraro A, Nuzzo F, Addeo R, Marano O, Incoronato P, De Placido S, Ciardiello F, Orditura M. Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety. Mol Clin Oncol. 2018 Sep;9(3):255-263. doi: 10.3892/mco.2018.1672. Epub 2018 Jul 16. PMID: 30155246; PMCID: PMC6109668.
Copy Download .nbib Format: NLM
PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?.

Frontiers in oncology

Franzese E, Diana A, Centonze S, Pignata S, De Vita F, Ciardiello F, Orditura M.
PMID: 32596142
Front Oncol. 2020 Jun 12;10:782. doi: 10.3389/fonc.2020.00782. eCollection 2020.

The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum-taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different...

Cite
Franzese E, Diana A, Centonze S, et al. PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. Front Oncol. 2020;10:782doi: 10.3389/fonc.2020.00782.
Franzese, E., Diana, A., Centonze, S., Pignata, S., De Vita, F., Ciardiello, F., & Orditura, M. (2020). PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. Frontiers in oncology, 10782. https://doi.org/10.3389/fonc.2020.00782
Franzese, Elisena, et al. "PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?." Frontiers in oncology vol. 10 (2020): 782. doi: https://doi.org/10.3389/fonc.2020.00782
Franzese E, Diana A, Centonze S, Pignata S, De Vita F, Ciardiello F, Orditura M. PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. Front Oncol. 2020 Jun 12;10:782. doi: 10.3389/fonc.2020.00782. eCollection 2020. PMID: 32596142; PMCID: PMC7303974.
Copy Download .nbib Format: NLM
First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age.

Journal of gastrointestinal oncology

Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, Laterza MM, Caterino M, Sforza V, Iranzo V, Biglietto M, Orditura M, Ciardiello F, Conzo G, Molino C, De Vita F.
PMID: 31602329
J Gastrointest Oncol. 2019 Oct;10(5):910-917. doi: 10.21037/jgo.2019.06.02.

BACKGROUND: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can...

Cite
Petrillo A, Pappalardo A, Calabrese F, et al. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol. 2019;10(5):910-917doi: 10.21037/jgo.2019.06.02.
Petrillo, A., Pappalardo, A., Calabrese, F., Tirino, G., Pompella, L., Ventriglia, J., Laterza, M. M., Caterino, M., Sforza, V., Iranzo, V., Biglietto, M., Orditura, M., Ciardiello, F., Conzo, G., Molino, C., & De Vita, F. (2019). First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. Journal of gastrointestinal oncology, 10(5), 910-917. https://doi.org/10.21037/jgo.2019.06.02
Petrillo, Angelica, et al. "First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age." Journal of gastrointestinal oncology vol. 10,5 (2019): 910-917. doi: https://doi.org/10.21037/jgo.2019.06.02
Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, Laterza MM, Caterino M, Sforza V, Iranzo V, Biglietto M, Orditura M, Ciardiello F, Conzo G, Molino C, De Vita F. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol. 2019 Oct;10(5):910-917. doi: 10.21037/jgo.2019.06.02. PMID: 31602329; PMCID: PMC6776800.
Copy Download .nbib Format: NLM
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).

Gynecologic oncology

Artioli G, Giannone G, Valabrega G, Maggiorotto F, Genta S, Pignata S, Lorusso D, Cormio G, Scalone S, Nicoletto MO, Greco F, Rossi E, Spagnoletti I, De Giorgi U, Orditura M, Mosconi AM, Kardhashi A, Bogliolo S, Borgato L.
PMID: 33888336
Gynecol Oncol. 2021 Jun;161(3):755-761. doi: 10.1016/j.ygyno.2021.04.014. Epub 2021 Apr 20.

OBJECTIVE: Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were described.METHODS: We...

Cite
Artioli G, Giannone G, Valabrega G, et al. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). Gynecol Oncol. 2021;161(3):755-761doi: 10.1016/j.ygyno.2021.04.014.
Artioli, G., Giannone, G., Valabrega, G., Maggiorotto, F., Genta, S., Pignata, S., Lorusso, D., Cormio, G., Scalone, S., Nicoletto, M. O., Greco, F., Rossi, E., Spagnoletti, I., De Giorgi, U., Orditura, M., Mosconi, A. M., Kardhashi, A., Bogliolo, S., & Borgato, L. (2021). Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). Gynecologic oncology, 161(3), 755-761. https://doi.org/10.1016/j.ygyno.2021.04.014
Artioli, Grazia, et al. "Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)." Gynecologic oncology vol. 161,3 (2021): 755-761. doi: https://doi.org/10.1016/j.ygyno.2021.04.014
Artioli G, Giannone G, Valabrega G, Maggiorotto F, Genta S, Pignata S, Lorusso D, Cormio G, Scalone S, Nicoletto MO, Greco F, Rossi E, Spagnoletti I, De Giorgi U, Orditura M, Mosconi AM, Kardhashi A, Bogliolo S, Borgato L. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). Gynecol Oncol. 2021 Jun;161(3):755-761. doi: 10.1016/j.ygyno.2021.04.014. Epub 2021 Apr 20. PMID: 33888336.
Copy Download .nbib Format: NLM
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.

Gastroenterology research and practice

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F.
PMID: 29983708
Gastroenterol Res Pract. 2018 Jun 10;2018:2373868. doi: 10.1155/2018/2373868. eCollection 2018.

BACKGROUND: High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer.METHODS: We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different...

Cite
Ventriglia J, Petrillo A, Huerta Alváro M, et al. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. Gastroenterol Res Pract. 2018;2018:2373868doi: 10.1155/2018/2373868.
Ventriglia, J., Petrillo, A., Huerta Alváro, M., Laterza, M. M., Savastano, B., Gambardella, V., Tirino, G., Pompella, L., Diana, A., Iovino, F., Troiani, T., Martinelli, E., Morgillo, F., Orditura, M., Cervantes, A., Ciardiello, F., & De Vita, F. (2018). Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. Gastroenterology research and practice, 20182373868. https://doi.org/10.1155/2018/2373868
Ventriglia, J, et al. "Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis." Gastroenterology research and practice vol. 2018 (2018): 2373868. doi: https://doi.org/10.1155/2018/2373868
Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. Gastroenterol Res Pract. 2018 Jun 10;2018:2373868. doi: 10.1155/2018/2373868. eCollection 2018. PMID: 29983708; PMCID: PMC6015665.
Copy Download .nbib Format: NLM
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.

ESMO open

Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T.
PMID: 29211816
ESMO Open. 2017 Jul 29;2(3):e000177. doi: 10.1136/esmoopen-2017-000177. eCollection 2017.

BACKGROUND: To investigate the potential predictors of response to regorafenib, in chemorefractory metastatic colorectal cancer (mCRC) patients with long-term efficacy from regorafenib treatment.METHODS: Retrospective, single institution analysis of patients with chemorefractory mCRC treated with regorafenib, in clinical practice setting....

Cite
Martinelli E, Sforza V, Cardone C, et al. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open. 2017;2(3):e000177doi: 10.1136/esmoopen-2017-000177.
Martinelli, E., Sforza, V., Cardone, C., Capasso, A., Nappi, A., Martini, G., Napolitano, S., Rachiglio, A. M., Normanno, N., Cappabianca, S., Reginelli, A., Bisceglie, M. D., Latiano, T. P., Maiello, E., Orditura, M., De Vita, F., Morgillo, F., Ciardiello, F., & Troiani, T. (2017). Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO open, 2(3), e000177. https://doi.org/10.1136/esmoopen-2017-000177
Martinelli, Erika, et al. "Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment." ESMO open vol. 2,3 (2017): e000177. doi: https://doi.org/10.1136/esmoopen-2017-000177
Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open. 2017 Jul 29;2(3):e000177. doi: 10.1136/esmoopen-2017-000177. eCollection 2017. PMID: 29211816; PMCID: PMC5703385.
Copy Download .nbib Format: NLM
Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M, Attademo L, Arenare L, Spina A, Russo D, Califano D, Losito NS, Setola SV, Franzese E, De Vita F, Orditura M, Pignata S.
PMID: 32796087
Int J Gynecol Cancer. 2021 Jan;31(1):110-113. doi: 10.1136/ijgc-2020-001540. Epub 2020 Aug 12.

BACKGROUND: Chemotherapy with carboplatin, paclitaxel, and bevacizumab is the standard therapy for patients with advanced stage ovarian cancer wild-type BRCA after primary surgery. The most frequent side effects of bevacizumab in this setting are hypertension, thrombosis, hemorrhage, and proteinuria,...

Cite
Ventriglia J, Paciolla I, Pisano C, et al. Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. Int J Gynecol Cancer. 2020;31(1):110-113doi: 10.1136/ijgc-2020-001540.
Ventriglia, J., Paciolla, I., Pisano, C., Tambaro, R., Cecere, S. C., Di Napoli, M., Attademo, L., Arenare, L., Spina, A., Russo, D., Califano, D., Losito, N. S., Setola, S. V., Franzese, E., De Vita, F., Orditura, M., & Pignata, S. (2021). Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 31(1), 110-113. https://doi.org/10.1136/ijgc-2020-001540
Ventriglia, Jole, et al. "Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 31,1 (2021): 110-113. doi: https://doi.org/10.1136/ijgc-2020-001540
Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M, Attademo L, Arenare L, Spina A, Russo D, Califano D, Losito NS, Setola SV, Franzese E, De Vita F, Orditura M, Pignata S. Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. Int J Gynecol Cancer. 2021 Jan;31(1):110-113. doi: 10.1136/ijgc-2020-001540. Epub 2020 Aug 12. PMID: 32796087.
Copy Download .nbib Format: NLM
Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response.

Frontiers in oncology

Franzese E, Centonze S, Diana A, Lombardi A, Carlino F, Guerrera LP, De Vita F, Caraglia M, Pignata S, Ciardiello F, Orditura M.
PMID: 31850198
Front Oncol. 2019 Nov 29;9:1289. doi: 10.3389/fonc.2019.01289. eCollection 2019.

No abstract available.

Cite
Franzese E, Centonze S, Diana A, et al. Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. Front Oncol. 2019;9:1289doi: 10.3389/fonc.2019.01289.
Franzese, E., Centonze, S., Diana, A., Lombardi, A., Carlino, F., Guerrera, L. P., De Vita, F., Caraglia, M., Pignata, S., Ciardiello, F., & Orditura, M. (2019). Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. Frontiers in oncology, 91289. https://doi.org/10.3389/fonc.2019.01289
Franzese, Elisena, et al. "Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response." Frontiers in oncology vol. 9 (2019): 1289. doi: https://doi.org/10.3389/fonc.2019.01289
Franzese E, Centonze S, Diana A, Lombardi A, Carlino F, Guerrera LP, De Vita F, Caraglia M, Pignata S, Ciardiello F, Orditura M. Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. Front Oncol. 2019 Nov 29;9:1289. doi: 10.3389/fonc.2019.01289. eCollection 2019. PMID: 31850198; PMCID: PMC6895028.
Copy Download .nbib Format: NLM
Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.

Cancers

Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F.
PMID: 30901943
Cancers (Basel). 2019 Mar 21;11(3). doi: 10.3390/cancers11030399.

Gastric cancer (GC) is the fifth-most common cancer worldwide and an important cause of cancer-related-death. The growing knowledge of its molecular pathogenesis has shown that GC is not a single entity, but a constellation of different diseases, each with...

Cite
Petrillo A, Pompella L, Tirino G, et al. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel). 2019;11(3)doi: 10.3390/cancers11030399.
Petrillo, A., Pompella, L., Tirino, G., Pappalardo, A., Laterza, M. M., Caterino, M., Orditura, M., Ciardiello, F., Lieto, E., Galizia, G., Castoro, C., & De Vita, F. (2019). Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers, 11(3), . https://doi.org/10.3390/cancers11030399
Petrillo, Angelica, et al. "Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions." Cancers vol. 11,3 (2019). doi: https://doi.org/10.3390/cancers11030399
Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel). 2019 Mar 21;11(3). doi: 10.3390/cancers11030399. PMID: 30901943; PMCID: PMC6468561.
Copy Download .nbib Format: NLM
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.

Oncology letters

Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C, DE Vita F.
PMID: 25789012
Oncol Lett. 2015 Apr;9(4):1628-1632. doi: 10.3892/ol.2015.2960. Epub 2015 Feb 12.

Sorafenib confers a survival benefit for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) A liver cirrhosis. At present, limited data exists with regard to the safety and efficacy of sorafenib in treating CP-B HCC patients. The present...

Cite
Federico A, Orditura M, Cotticelli G, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015;9(4):1628-1632doi: 10.3892/ol.2015.2960.
Federico, A., Orditura, M., Cotticelli, G., DE Sio, I., Romano, M., Gravina, A. G., Dallio, M., Fabozzi, A., Ciardiello, F., Loguercio, C., & DE Vita, F. (2015). Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncology letters, 9(4), 1628-1632. https://doi.org/10.3892/ol.2015.2960
Federico, Alessandro, et al. "Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis." Oncology letters vol. 9,4 (2015): 1628-1632. doi: https://doi.org/10.3892/ol.2015.2960
Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C, DE Vita F. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015 Apr;9(4):1628-1632. doi: 10.3892/ol.2015.2960. Epub 2015 Feb 12. PMID: 25789012; PMCID: PMC4356395.
Copy Download .nbib Format: NLM
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting.

Oncotarget

Prete SD, Montella L, Arpino G, Buono G, Buonerba C, Dolce P, Fiorentino O, Aliberti M, Febbraro A, Savastano C, Colantuoni G, Riccardi F, Ruggiero A, Placido S, Orditura M.
PMID: 32547706
Oncotarget. 2020 Jun 02;11(22):2083-2091. doi: 10.18632/oncotarget.27603. eCollection 2020 Jun 02.

Despite relevant medical advancements, metastatic breast cancer remains an uncurable disease. HER2 signaling conditions tumor behavior and treatment strategies of HER2 expressing breast cancer. Cancer treatment guidelines uniformly identify dual blockade with pertuzumab and trastuzumab plus a taxane as...

Cite
Prete SD, Montella L, Arpino G, et al. Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget. 2020;11(22):2083-2091doi: 10.18632/oncotarget.27603.
Prete, S. D., Montella, L., Arpino, G., Buono, G., Buonerba, C., Dolce, P., Fiorentino, O., Aliberti, M., Febbraro, A., Savastano, C., Colantuoni, G., Riccardi, F., Ruggiero, A., Placido, S., & Orditura, M. (2020). Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget, 11(22), 2083-2091. https://doi.org/10.18632/oncotarget.27603
Prete, Salvatore Del, et al. "Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting." Oncotarget vol. 11,22 (2020): 2083-2091. doi: https://doi.org/10.18632/oncotarget.27603
Prete SD, Montella L, Arpino G, Buono G, Buonerba C, Dolce P, Fiorentino O, Aliberti M, Febbraro A, Savastano C, Colantuoni G, Riccardi F, Ruggiero A, Placido S, Orditura M. Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget. 2020 Jun 02;11(22):2083-2091. doi: 10.18632/oncotarget.27603. eCollection 2020 Jun 02. PMID: 32547706; PMCID: PMC7275781.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries